FDA has approved Truxima (rituximab-abbs, Celltrion Inc.) as the first biosimilar to Rituxan (rituximab, Genentech Inc.) for patients with CD20-positive, B-cell non-Hodgkin's lymphoma to be used as a single agent or in combination with chemotherapy.
The latest results from an ongoing clinical study incorporating the immunotherapy SurVaxM as part of combination treatment for glioblastoma show that the investigational drug is safe, well-tolerated and extended survival even among the hardest-to-treat subgroups of patients.
Merck KGaA, Darmstadt, Germany, and Pfizer Inc. announced the phase III JAVELIN Ovarian 200 trial evaluating avelumab alone or in combination with pegylated liposomal doxorubicin, a type of chemotherapy, compared with PLD did not meet the prespecified primary endpoints of overall survival or progression-free survival in patients with platinum-resistant or -refractory ovarian cancer.
The Pancreatic Cancer Collective, a strategic partnership of the Lustgarten Foundation and Stand Up To Cancer, has awarded a total of $7 million in first-round “New Therapies Challenge” grants to seven teams of cancer researchers to explore new pancreatic cancer treatments.
Oren Cahlon, a radiation oncologist and an expert in proton therapy, was named associate deputy physician-in-chief for the Memorial Sloan Kettering Cancer Center MSK Regional Care Network.
Weill Cornell Medicine has been awarded a five-year, $9 million Program Project Grant from NCI to better understand how and why patients with an aggressive and incurable form of lymphoma initially respond to treatment, only to relapse over time.
The National Comprehensive Cancer Network announced the Abramson Cancer Center of the University of Pennsylvania will become the organization's 28th member institution.
Four new CPRIT Scholar grants totaling $16 million were awarded. The grants will support the recruitment of investigators researching cancers of the brain and digestive system as well as experts in the field of immunotherapy.
The Huntsman Cancer Institute at the University of Utah has begun construction on a project that will house the region's first proton therapy center.
David Kerstein was named chief medical officer at Anchiano Therapeutics Inc., a clinical-stage biopharmaceutical company.
